Edgar Filing: Studer Jacqueline - Form 4

Studer Jacq Form 4	•										
February 27										OMB AF	PROVAL
FORM	VI 4 UNITED	STATES							OMMISSION	OMB Number:	3235-0287
Washington, D.C. 20549Check this box if no longer subject to Section 16.Form 4 or Form 5 obligations may continue.See Instruction 						Expires: Estimated a burden hour response	0				
(Print or Type	Responses)										
1. Name and Studer Jaco	Address of Reporting queline	Person <u>*</u>	Symbol	K LAB		d Ticker o RATORI			5. Relationship of F Issuer (Check	Reporting Pers	
(Last)	(First) (XX DRIVE	Middle)	3. Date of (Month/ 02/25/2	Day/Ye		ransactio	1	·	Director X Officer (give t below) CVP, Gen. C		Owner r (specify retary
WESTBRO	(Street) DOK, ME 04092		4. If Am Filed(Mo			Date Origin ar)	ıal		6. Individual or Joi Applicable Line) _X_ Form filed by Ou Form filed by Mo Person	ne Reporting Per	son
(City)	(State)	(Zip)	Tał	ole I - N	on-	Derivativ	e Seci		ired, Disposed of,	or Beneficiall	v Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deem Execution any (Month/Da	ed Date, if	3. Transa Code (Instr.	actic 8)		ties A sed of	cquired (A)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. 7. Nature of Ownership Indirect Form: Beneficial Direct (D) Ownership or Indirect (Instr. 4) (I) (Instr. 4)	
Common Stock	02/25/2019			M	·	1,156	(D) A	\$ 79.54	6,918	D	
Common Stock	02/25/2019			S		1,223	D	\$ 211.6985 (1)	5 5,695	D	
Common Stock	02/25/2019			S		472	D	\$ 212.0522	5,223	D	
Common Stock	02/26/2019			S		834	D	\$ 208.0617 (2)	7 4,389	D	

Edgar Filing: Studer Jacqueline - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number on f Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amoun or Number of Shares
Incentive Stock Option (right-to-buy)	\$ 79.54	02/25/2019		М	1,156	(3)	02/13/2025	Common Stock	1,156

Reporting Owners

Reporting Owner Name / Address	Relationships							
	Director	10% Owner	Officer	Other				
Studer Jacqueline ONE IDEXX DRIVE WESTBROOK, ME 04092			CVP, Gen. Counsel & Secretary					
Signatures								
/s/ Lily J. Lu, Attorney-in-Fact for Studer	02/27/2019							
<u>**</u> Signature of Reporting Perso	on]	Date					

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Represents the weighted average sales price of the shares sold ranging from a low of \$211.00 to a high of \$211.96 per share. The (1) undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Represents the weighted average sales price of the shares sold ranging from a low of \$208.00 to a high of \$208.23 per share. The (2) undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Edgar Filing: Studer Jacqueline - Form 4

Grant of option to buy 3,140 shares of IDEXX Laboratories, Inc. common stock that vests and is exercisable in five annual installments beginning on February 14, 2016, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred

- (3) beginning on February 14, 2016, without giving effect to the 2-tor-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
- (4) Not applicable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.